Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Aclarion Inc (ACON)

Aclarion Inc (ACON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event Newsfile - Tue Jan 17, 2023

Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"),  a healthcare technology company that is leveraging biomarkers...

ACON : 0.3239 (+5.85%)
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan AccessWire - Wed Jul 20, 2022

Initial findings from the EVAL study are expected to be released in Q4 2022

ACON : 0.3239 (+5.85%)
ACONW : 0.0330 (+11.49%)
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain AccessWire - Wed Jun 22, 2022

Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years

ACON : 0.3239 (+5.85%)
ACONW : 0.0330 (+11.49%)
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering AccessWire - Tue Apr 26, 2022

SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"),...

ACON : 0.3239 (+5.85%)
ACONW : 0.0330 (+11.49%)
Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering AccessWire - Thu Apr 21, 2022

SAN MATEO, CA / ACCESSWIRE / April 21, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"),...

ACON : 0.3239 (+5.85%)
ACONW : 0.0330 (+11.49%)

Barchart Exclusives

Tesla Stock Forecast Post-Q2 Earnings: 'Present Imperfect, Future Uncertain' Barchart - 21 minutes ago
Tesla stock crashed following its Q2 earnings earlier this week. Here are the key takeaways from the report, and the forecast for the company amid a challenging macro environment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot